Search

Your search keyword '"Macaluso, F."' showing total 386 results
Start Over Author "Macaluso, F."
386 results on '"Macaluso, F."'

1. Lack of Seroconversion Following COVID-19 Vaccination Is an Independent Risk Factor for SARS-CoV-2 Infection in Patients With Inflammatory Bowel Disease: Data from ESCAPE-IBD, an IG-IBD Study

Author

Macaluso, F, Principi, M, Facciotti, F, Contaldo, A, Todeschini, A, Saibeni, S, Bezzio, C, Castiglione, F, Nardone, O, Spagnuolo, R, Fantini, M, Riguccio, G, Conforti, S, Caprioli, F, Vigano, C, Felice, C, Fiorino, G, Correale, C, Bodini, G, Milla, M, Scardino, G, Vernero, M, Desideri, F, Bossa, F, Guerra, M, Ventimiglia, M, Casa, A, Rizzo, G, Orlando, A, Amato, A, Ascolani, M, Calabrese, G, Comberlato, M, De Bona, M, Demarzo, M, Doldo, P, Dragoni, G, Furfaro, F, Laffusa, A, Martino, G, Mulinacci, G, Olmo, O, O'Sed, N, Paba, S, Radice, S, Renna, S, Ribaldone, D, MacAluso F. S., Principi M., Facciotti F., Contaldo A., Todeschini A., Saibeni S., Bezzio C., Castiglione F., Nardone O. M., Spagnuolo R., Fantini M. C., Riguccio G., Conforti S., Caprioli F., Vigano C., Felice C., Fiorino G., Correale C., Bodini G., Milla M., Scardino G., Vernero M., Desideri F., Bossa F., Guerra M., Ventimiglia M., Casa A., Rizzo G., Orlando A., Amato A., Ascolani M., Calabrese G., Comberlato M., De Bona M., Demarzo M. G., Doldo P., Dragoni G., Furfaro F., Laffusa A., Martino G., Mulinacci G., Olmo O., O'Sed N. P., Paba S., Radice S., Renna S., Ribaldone D. G., Macaluso, F, Principi, M, Facciotti, F, Contaldo, A, Todeschini, A, Saibeni, S, Bezzio, C, Castiglione, F, Nardone, O, Spagnuolo, R, Fantini, M, Riguccio, G, Conforti, S, Caprioli, F, Vigano, C, Felice, C, Fiorino, G, Correale, C, Bodini, G, Milla, M, Scardino, G, Vernero, M, Desideri, F, Bossa, F, Guerra, M, Ventimiglia, M, Casa, A, Rizzo, G, Orlando, A, Amato, A, Ascolani, M, Calabrese, G, Comberlato, M, De Bona, M, Demarzo, M, Doldo, P, Dragoni, G, Furfaro, F, Laffusa, A, Martino, G, Mulinacci, G, Olmo, O, O'Sed, N, Paba, S, Radice, S, Renna, S, Ribaldone, D, MacAluso F. S., Principi M., Facciotti F., Contaldo A., Todeschini A., Saibeni S., Bezzio C., Castiglione F., Nardone O. M., Spagnuolo R., Fantini M. C., Riguccio G., Conforti S., Caprioli F., Vigano C., Felice C., Fiorino G., Correale C., Bodini G., Milla M., Scardino G., Vernero M., Desideri F., Bossa F., Guerra M., Ventimiglia M., Casa A., Rizzo G., Orlando A., Amato A., Ascolani M., Calabrese G., Comberlato M., De Bona M., Demarzo M. G., Doldo P., Dragoni G., Furfaro F., Laffusa A., Martino G., Mulinacci G., Olmo O., O'Sed N. P., Paba S., Radice S., Renna S., and Ribaldone D. G.

Abstract

This prospective study reported 2 key results: (1) lack of seroconversion following 2 doses of COVID-19 vaccines is an independent predictor of SARS-CoV-2 infection; (2) treatments for IBD were not associated with increased risk of SARS-CoV-2 infection.

Published
2024

3. OC.18.7: HIDDEN SHORT BOWEL SYNDROME IN CROHN'S DISEASE: A NATIONAL SURVEY

Author

Pessarelli, T., primary, Topa, M., additional, Pugliese, D., additional, Macaluso, F., additional, Orlando, A., additional, Saibeni, S., additional, Costantino, A., additional, Sorge, A., additional, Scaramella, L., additional, Nandi, N., additional, Vecchi, M., additional, Caprioli, F., additional, and Elli, L., additional

Published
2024
Full Text
View/download PDF

4. The management of patients with inflammatory bowel disease-associated spondyloarthritis: Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD) and Italian Society of Rheumatology (SIR) recommendations based on a pseudo-Delphi consensus

Author

Macaluso, F, Caprioli, F, Benedan, L, Bezzio, C, Caporali, R, Cauli, A, Chimenti, M, Ciccia, F, D'Angelo, S, Fantini, M, Festa, S, Iannone, F, Lubrano, E, Mariani, P, Papi, C, Provenzano, G, Pugliese, D, Rispo, A, Saibeni, S, Salvarani, C, Variola, A, Zenga, M, Armuzzi, A, Orlando, A, Gerli, R, Macaluso, Fabio Salvatore, Caprioli, Flavio, Benedan, Laura, Bezzio, Cristina, Caporali, Roberto, Cauli, Alberto, Chimenti, Maria Sole, Ciccia, Francesco, D'Angelo, Salvatore, Fantini, Massimo Claudio, Festa, Stefano, Iannone, Florenzo, Lubrano, Ennio, Mariani, Paolo, Papi, Claudio, Provenzano, Giuseppe, Pugliese, Daniela, Rispo, Antonio, Saibeni, Simone, Salvarani, Carlo, Variola, Angela, Zenga, Mariangela, Armuzzi, Alessandro, Orlando, Ambrogio, Gerli, Roberto, Macaluso, F, Caprioli, F, Benedan, L, Bezzio, C, Caporali, R, Cauli, A, Chimenti, M, Ciccia, F, D'Angelo, S, Fantini, M, Festa, S, Iannone, F, Lubrano, E, Mariani, P, Papi, C, Provenzano, G, Pugliese, D, Rispo, A, Saibeni, S, Salvarani, C, Variola, A, Zenga, M, Armuzzi, A, Orlando, A, Gerli, R, Macaluso, Fabio Salvatore, Caprioli, Flavio, Benedan, Laura, Bezzio, Cristina, Caporali, Roberto, Cauli, Alberto, Chimenti, Maria Sole, Ciccia, Francesco, D'Angelo, Salvatore, Fantini, Massimo Claudio, Festa, Stefano, Iannone, Florenzo, Lubrano, Ennio, Mariani, Paolo, Papi, Claudio, Provenzano, Giuseppe, Pugliese, Daniela, Rispo, Antonio, Saibeni, Simone, Salvarani, Carlo, Variola, Angela, Zenga, Mariangela, Armuzzi, Alessandro, Orlando, Ambrogio, and Gerli, Roberto

Abstract

Spondyloarthritis (SpA) is the most frequent extraintestinal manifestation in patients with inflammatory bowel diseases (IBD). When IBD and spondyloarthritis coexist, musculoskeletal and intestinal disease features should be considered when planning a therapeutic strategy. Treatment options for IBD and SpA have expanded enormously over the last few years, but randomized controlled trials with specific endpoints focused on SpA are not available in the IBD setting. To address this important clinical topic, the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD) and the Italian Society of Rheumatology (SIR) jointly planned to draw updated therapeutic recommendations for IBD-associated SpA using a pseudo-Delphi method. This document presents the official recommendations of IG-IBD and SIR on the management of IBD-associated SpA in the form of 34 statements and 4 therapeutic algorithms. It is intended to be a reference guide for gastroenterologists and rheumatologists dealing with IBD-associated SpA.

Published
2024

5. Safety, hesitancy of coronavirus disease 2019 vaccination and pandemic burden in patients with inflammatory bowel disease: Data of a national study (ESCAPE-IBD)

Author

Principi, M, Macaluso, F, Todeschini, A, Facciotti, F, Contaldo, A, Castiglione, F, Nardone, O, Spagnuolo, R, Doldo, P, Riguccio, G, Conforti, F, Vigano, C, Ascolani, M, Fiorino, G, Correale, C, Bodini, G, Milla, M, Scardino, G, Vernero, M, Desideri, F, Caprioli, F, Mannino, M, Rizzo, G, Orlando, A, Principi M., Macaluso F. S., Todeschini A., Facciotti F., Contaldo A., Castiglione F., Nardone O. M., Spagnuolo R., Doldo P., Riguccio G., Conforti F. S., Vigano C., Ascolani M., Fiorino G., Correale C., Bodini G., Milla M., Scardino G., Vernero M., Desideri F., Caprioli F., Mannino M., Rizzo G., Orlando A., Principi, M, Macaluso, F, Todeschini, A, Facciotti, F, Contaldo, A, Castiglione, F, Nardone, O, Spagnuolo, R, Doldo, P, Riguccio, G, Conforti, F, Vigano, C, Ascolani, M, Fiorino, G, Correale, C, Bodini, G, Milla, M, Scardino, G, Vernero, M, Desideri, F, Caprioli, F, Mannino, M, Rizzo, G, Orlando, A, Principi M., Macaluso F. S., Todeschini A., Facciotti F., Contaldo A., Castiglione F., Nardone O. M., Spagnuolo R., Doldo P., Riguccio G., Conforti F. S., Vigano C., Ascolani M., Fiorino G., Correale C., Bodini G., Milla M., Scardino G., Vernero M., Desideri F., Caprioli F., Mannino M., Rizzo G., and Orlando A.

Abstract

Background and aims The purpose of this study was to present data on the safety of anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination in a cohort of inflammatory bowel disease (IBD) patients of an ongoing multicenter study (ESCAPE-IBD) sponsored by the Italian Group for the study of Inflammatory Bowel Disease (ClinicalTrials.gov Identifier: NCT04769258). Methods Anti-SARS-CoV-2 vaccination was administrated to 809 IBD patients. Interviews were conducted to report adverse events related to vaccination. Of these 809, 346 patients were surveyed on the pandemic burden and the main reason for hesitancy in coronavirus disease 2019 vaccination. The chi-square test was used to compare categorical variables. Logistic regression was used to assess the relationship between disease-related characteristics and the onset of adverse events. Results About 45% of patients had at least one side effect, following the first dose (10%), the second (15%), and both doses (19%). All the adverse events were mild and lasted only a few days. Logistic regression analysis revealed that female sex (P < 0.001), younger age (P = 0.001), seroconversion (P = 0.002), and comorbidity (P < 0.001) were significantly associated with adverse events. The survey showed that the main concerns were the possibility of adverse event (33%). Almost all patients (99%) felt safer having been vaccinated at their IBD reference center. Conclusion The vaccine reactions experienced in IBD patients were mostly self-limited. We found high acceptance and good safety of SARS-CoV-2 vaccination in our cohort.

Published
2023

6. Reduced humoral response to two doses of COVID-19 vaccine in patients with inflammatory bowel disease: Data from ESCAPE-IBD, an IG-IBD study

Author

Macaluso, F, Principi, M, Facciotti, F, Contaldo, A, Todeschini, A, Saibeni, S, Bezzio, C, Castiglione, F, Nardone, O, Spagnuolo, R, Fantini, M, Riguccio, G, Caprioli, F, Vigano, C, Felice, C, Fiorino, G, Correale, C, Bodini, G, Milla, M, Scardino, G, Vernero, M, Desideri, F, Mannino, M, Rizzo, G, Orlando, A, Amato, A, Ascolani, M, Calabrese, G, Casa, A, Comberlato, M, Conforti, F, De Bona, M, Demarzo, M, Doldo, P, Dragoni, G, Furfaro, F, Mulinacci, G, Olmo, O, O'Sed, N, Paba, S, Radice, S, Renna, S, Ribaldone, D, Rizzuto, G, Macaluso F. S., Principi M., Facciotti F., Contaldo A., Todeschini A., Saibeni S., Bezzio C., Castiglione F., Nardone O. M., Spagnuolo R., Fantini M. C., Riguccio G., Caprioli F., Vigano C., Felice C., Fiorino G., Correale C., Bodini G., Milla M., Scardino G., Vernero M., Desideri F., Mannino M., Rizzo G., Orlando A., Amato A., Ascolani M., Calabrese G., Casa A., Comberlato M., Conforti F. S., De Bona M., Demarzo M. G., Doldo P., Dragoni G., Furfaro F., Mulinacci G., Olmo O., O'Sed N. P., Paba S., Radice S., Renna S., Ribaldone D. G., Rizzuto G., Macaluso, F, Principi, M, Facciotti, F, Contaldo, A, Todeschini, A, Saibeni, S, Bezzio, C, Castiglione, F, Nardone, O, Spagnuolo, R, Fantini, M, Riguccio, G, Caprioli, F, Vigano, C, Felice, C, Fiorino, G, Correale, C, Bodini, G, Milla, M, Scardino, G, Vernero, M, Desideri, F, Mannino, M, Rizzo, G, Orlando, A, Amato, A, Ascolani, M, Calabrese, G, Casa, A, Comberlato, M, Conforti, F, De Bona, M, Demarzo, M, Doldo, P, Dragoni, G, Furfaro, F, Mulinacci, G, Olmo, O, O'Sed, N, Paba, S, Radice, S, Renna, S, Ribaldone, D, Rizzuto, G, Macaluso F. S., Principi M., Facciotti F., Contaldo A., Todeschini A., Saibeni S., Bezzio C., Castiglione F., Nardone O. M., Spagnuolo R., Fantini M. C., Riguccio G., Caprioli F., Vigano C., Felice C., Fiorino G., Correale C., Bodini G., Milla M., Scardino G., Vernero M., Desideri F., Mannino M., Rizzo G., Orlando A., Amato A., Ascolani M., Calabrese G., Casa A., Comberlato M., Conforti F. S., De Bona M., Demarzo M. G., Doldo P., Dragoni G., Furfaro F., Mulinacci G., Olmo O., O'Sed N. P., Paba S., Radice S., Renna S., Ribaldone D. G., and Rizzuto G.

Abstract

Background: Patients on immunosuppressive drugs have been excluded from COVID-19 vaccines trials, creating concerns regarding their efficacy. Aims: To explore the humoral response to COVID-19 vaccines in patients with inflammatory bowel disease (IBD) Methods: Effectiveness and Safety of COVID-19 Vaccine in Patients with Inflammatory Bowel Disease (IBD) Treated with Immunomodulatory or Biological Drugs (ESCAPE-IBD) is a prospective, multicentre study promoted by the Italian Group for the study of Inflammatory Bowel Disease. We present data on serological response eight weeks after the second dose of COVID-19 vaccination in IBD patients and healthy controls (HCs). Results: 1076 patients with IBD and 1126 HCs were analyzed. Seropositivity for anti-SARS-CoV-2 IgG was reported for most IBD patients, even if with a lesser rate compared with HCs (92.1% vs. 97.9%; p<0.001). HCs had higher antibody concentrations (median OD 8.72 [IQR 5.2-14-2]) compared to the whole cohort of IBD patients (median OD 1.54 [IQR 0.8-3.6]; p<0.001) and the subgroup of IBD patients (n=280) without any treatment or on aminosalicylates only (median OD 1.72 [IQR 1.0–4.1]; p<0.001). Conclusions: Although most IBD patients showed seropositivity after COVID-19 vaccines, the magnitude of the humoral response was significantly lower than in HCs. Differently from other studies, these findings seem to be mostly unrelated to the use of immune-modifying treatments (ClinicalTrials.govID:NCT04769258).

Published
2023

10. Perception and management of liver enzymes abnormalities among IBD specialists: Insights from an IG-IBD survey.

Author

Pugliese, N., Bezzio, C., Polverini, D., Festa, S., Caprioli, F.A., Renna, S., Savarino, E., Variola, A., Fantini, M. Claudio, Pugliese, D., Macaluso, F., Buono, A. Dal, Masetti, C., Gabbiadini, R., Loy, L., Armuzzi, A., and Aghemo, A.

Abstract

Liver diseases are common in patients with Inflammatory Bowel Diseases (IBD). Despite their burden, little is known about how specialists perceive and manage liver enzyme abnormalities. This study investigates current practices, challenges, and educational needs of IBD specialists in the management of liver enzyme abnormalities. A 22-question web-based survey was distributed to IG-IBD member physicians, covering their demographics, workplace features and approach to managing liver enzyme abnormalities in The survey was completed by 205/439 (46.7%) participants. The majority of respondents were over 45 years old (39%) and worked in Northern Italy (62%). Most were gastroenterologists (86%) working in public community hospitals (46%), with only 21% having a dedicated Liver Unit with a clear referral pathway for IBD patients. Forty-eight percent of physicians reported regular monitoring of liver enzymes such as AST and ALT at each visit, while 41% similarly monitored GGT and 28% monitored ALP (with 24% monitoring it only in the presence of signs of liver disease). In the case of abnormal liver enzymes, over 70% chose to order additional tests independently. The conditions considered most likely in case of mild transaminase elevations were metabolic dysfunction-associated steatotic liver disease (MASLD) (71%) and drug-induced liver injury (DILI) (17%). The least likely diagnosis was porto-sinusoidal vascular disorder (PSVD; 58%). Routine upper abdominal ultrasound was performed only by 50% of physicians. A significant proportion of physicians (57%) reported that their training in the management of liver enzyme abnormalities was adequate, but they would benefit from additional education. The main barriers identified were a lack of specific guideline (62%) and limited access to tools for in-depth diagnosis (52%). This survey reveals heterogeneity in monitoring and management of liver enzyme abnormalities among IBD specialists. Most physicians recognize the need for improved training and guidelines. [ABSTRACT FROM AUTHOR]

Published
2025
Full Text
View/download PDF

16. Azathioprine for prevention of clinical recurrence in Crohn's disease patients with severe endoscopic recurrence: an IG-IBD randomized double-blind trial

Author

Orlando, A, Mocciaro, F, Ventimiglia, M, Renna, S, Rispo, A, Scribano, M, Testa, A, Aratari, A, Bossa, F, Angelucci, E, Onali, S, Cappello, M, Giunta, M, Scimeca, D, Macaluso, F, Castiglione, F, Papi, C, Annese, V, Biancone, L, Kohn, A, Di Mitri, R, and Cottone, M

Subjects
Settore MED/12, Crohn Disease, Double-Blind Method, Recurrence, Azathioprine, Humans, Mesalamine
Abstract

The recurrence of Crohn's Disease after ileo-colonic resection is a crucial issue. Severe endoscopic lesions increase the risk of developing early symptoms. Prevention and treatment of post-operative Endoscopic Recurrence (ER) have been studied with conflicting results. We compare effi cacy of azathioprine (AZA) vs. high-dose 5-aminosalicylic acid (5-ASA) in preventing clinical recurrence and treating severe post-operative ER.We performed a 1-year multicenter randomized double-blind double-dummy trial. Primary end-points were endoscopic improvement and therapeutic failure (clinical recurrence or drug discontinuation due to lack of efficacy or adverse events) 12 months after randomization. We also performed a post-trial analysis on symptomatic and endoscopic outcomes 10 years after the beginning of the trial, with a median follow-up of 60 months.Therapeutic failure occurred in 8 patients (17.4%) within 12 months from randomization, with no significant difference between patients treated with 5-ASA (20.8%, 5 patients) and those with AZA (13.6%, 3 patients). Therapeutic failure was due to clinical recurrence in the 5-ASA group and to adverse events in the AZA group. Endoscopic improvement at 12 months was observed in 8 patients, 2 (11.8%) in the 5-ASA group and 6 (30%) in the AZA group. No serious adverse event was recorded. At the post-trial analysis (median follow-up 60 months), 47.8% (22/46) of patients experienced clinical recurrence: 54.2% (13/24) in the 5-ASA group and 40.9% (9/22) in the AZA group, p=0.546. Patients treated with AZA had lower risk of drug escalation. Clinical recurrence was associated with smoking (p=0.031) and previous surgery (p=0.003).Our trial indicates that there was no difference in terms of treatment failure between 5-ASA and AZA in patients with severe ER. The main limit of AZA is its less favorable safety profile.

Published
2020

17. Poster presentation

Author

Duparc, F., Noyon, M., Ozeel, J., Gerometta, A., Michot, C., Tadjalli, M., Moslemy, H., Safaei, S., Heiman, A., Wish-Baratz, S., Melnikov, T., Smoliar, E., Hakan, A. Y., Yucel, F., Kachlík, D. K., Pešl, M. P., Báča, V. B., Stingl, J. S., Kachlík, K. D., Čech, Č. P., Báča, B. V., Mompeó, B., Marrero-Rodriguez, A., Zeybek, A., Sağlam, B., Çikler, E., Çetinel, Ş., Ercan, F., Şener, G., Kawawa, Y., Kohda, E., Tatsuya, T., Moroi, M., Kunimasa, T., Nagamoto, M., Terada, H., Labuschagne, B. C. J., van der Krieke, T. J., Hoogland, P. V., Muller, C. J. F., Lyners, R., Vorster, W., Matusz, P., Zaboi, D. E., Xu, S. C., Tu, L. L., Wang, Q., Zhang, M., Han, H., Tao, W., Jiao, Y., Pang, G., Aydin, M. E., Kopuz, C., Demir, M. T., Yildirim, M., Kale, A., Ince, Y., Khamanarong, K., Jeeravipoolvarn, P., Chaijaroonkhanarak, W., Gawgleun, W., Fujino, T., Uz, A., Apaydin, N., Bozkurt, M., Elhan, A., Sheibani, M. T., Adibmoradi, M., Jahovic, N., Alican, I., Erkanli, G., Arbak, S., Karakaş, S., Taşer, F., Güneş, H., Yildiz, Y., Yazici, Y., Aland, R. C., Kippers, V., Song, W. C., Park, S. H., Shin, C., Koh, K. S., Russo, G., Pomara, F., Veca, M., Cacciola, F., Martorana, U., Gravante, G., Tobenas-Dujardin, A. C., Laquerrière, A., Muller, J. M., Fréger, P., López-Serna, N., Álvarez-González, E., Torres-Gonzàlez, V., Laredo-López, G., Esparza-González, G. V., Álvarez-Cantú, R., Garza-González, C. E., Guzmán-López, S., Aldur, M. M., Çelik, H. H., Sürücü, S., Denk, C., Yang, H. J., Gil, Y. C., Kim, T. J., Lee, H. Y., Lee, W. J., Lee, H., Hu, K. S., Akita, K., Kim, H. J., Jung, H. S., Gurbuz, H., Balik, S., Wavreille, G., Chantelot, C., Demondion, X., Fontaine, C., Çavdar, S., Yalin, A., Saka, E., Özdoǧmuş, Ö., Çakmak, Ö., Elevli, L., Saǧlam, B., Coquerel-Beghin, D., Milliez, P. Y., Lemierre, G., Oktem, G., Vatansever, S., Ayla, S., Uysal, A., Aktas, S., Karabulut, B., Bilir, A., Uslu, S., Aktug, H., Yurtseven, M. E., Celik, H. H., Tatar, I., Surucu, S., Karaduman, A., Tunali, S., Neuhüttler, S., Kröll, A., Moriggl, B., Brenner, E., Loukas, M., Arora, S., Louis, Jr, R. G., Fogg, Q. A., Wagner, T., Tedman, R. A., Ching, H. Y., Eze, N., Bottrill, I. D., Blyth, P., Faull, R. L. M., Vuletic, J., Elizondo-Omaña, R. E., Rodríguez, M. A. García, López, S. Guzmán, de la Garza, O. Tijerina, Liu, Y. H., Zhang, K. L., Lu, D. H., Kwak, H. H., Park, H. D., Youn, K. H., Kang, H. J., Kang, H. C., Han, S. H., Ikiz, Z. A. Aktan, Ucerler, H., Uygur, M., Kutoglu, T., Dina, C., Iliescu, D., Şapte, E., Bordei, P., Lekšan, I., Marcikić, M., Radić, R., Nikolić, V., Kurbel, S., Selthofer, R., Báča, V., Doubková, A., Kachlík, D., Stingl, J., Džupa, V., Grill, R., Nam, Y. S., Paik, D. J., Shin, C. S., Kim, S. J., Kim, D. G., Jin, C. S., Kim, D. I., Lee, U. Y., Kwak, D. S., Lee, J. H., Han, C. H., Carpino, A., Rago, V., Romeo, F., Carani, C., Andò, S., Arican, R. Y., Coskun, N., Sarikcioglu, L., Sindel, M., Arican, Y. R., Altun, U., Ozsoy, U., Oguz, N., Yildirim, F. B., Nakajima, K., Duygulu, E., Aydin, H., Gurer, E. Inanc, Ozkan, O., Tuzuner, S., Özsoy, U., Çubukçu, S., Demirel, B. M., Akkin, S. M., Marur, T., Weiglein, A. H., Maghiar, T. T., Borza, C., Bumbu, A., Bumbu, G., Polle, G., Auquit-Auckbur, I., Dujardin, F., Biga, N., Olivier, E., Defives, T., Ghazali, S., Anastasi, G., Rizzo, G., Favaloro, A., Miliardi, D., Giacobbe, O., Santoro, G., Trimarchi, F., Cutroneo, G., Govsa, F., Bilge, O., Ozer, M. A., Erdogmus, S., Grizzi, F., Pelillo, F., Mori, M., Franceschini, B., Portinaro, N., Godlewski, G., Viala, M., Rouanet, J. P., Prat, D., Rahmé, Z. S., Prudhomme, M., Eken, E., Kwiatkowska, M., Liegmann, J., Chmielewski, R., Grimmond, J., Kwiatkowski, M., Schintler, M. V., Windisch, G., Wittgruber, G., Prandl, E. C., Prodinger, P., Anderhuber, F., Scharnagl, E., Gerbino, A., Buscemi, M., Leone, A., Mandracchia, R., Peri, G., Lipari, D., Farina-Lipari, E., Valentino, B., D’Arpa, S., Cordova, A., Bucchieri, F., Ribbene, A., David, S., Palma, A., Davies, D. E., Haitchi, H. M., Holgate, S. T., La Rocca, G., Anzalone, R., Campanella, C., Rappa, F., Bartolotta, T., Cappello, F., Bellafiore, M., Sivverini, G., Palumbo, D., Macaluso, F., Farina, F., Di Felice, V., Montalbano, A., Ardizzone, N., Marcianò, V., Zummo, G., Tanyeli, E., Üzel, M., Carini, F., Scardina, G. A., Varia, P., Valenza, V., Messina, P., Meiring, J. H., Schumann, C., Whitmore, I., Greyling, L. M., Hamel, O., Hamel, A., Robert, R., Garçon, M., Lagier, S., Blin, Y., Armstrong, O., Rogez, J. M., Le Borgne, J., Ifrim, C. Feng, Maghiar, A., Botea, M., Ifrim, M., Pop, O., Sandor, M., Behdadipour, Z., Saberi, M., Esfandiary, E., Gentile, C., Marconi, A., Livrea, M. A., Uzan, G., D’Alessio, P., Ridola, C. G., Grassi, N., Pantuso, G., Bottino, A., Cacace, E., Li Petri, S., Di Gaudio, F., Guercio, G., Latteri, M. A., Nobile, D., Cipolla, C., Caruso, G., Salvaggio, G., Lo Cascio, A., Fatta, G., Lagalla, R., Campisi, A., Verderame, F., Martegani, A., Cardinale, A. E., and Luedinghausen, M. V.

Published
2005
Full Text
View/download PDF

18. P439 Effectiveness of Ustekinumab on Crohn’s disease associated spondyloartropathy: real-world data from the Sicilian Network for Inflammatory Bowel Diseases (SN-IBD)

Author

Macaluso, F, primary, Fries, W, additional, Viola, A, additional, Costantino, G, additional, Muscianisi, M, additional, Cappello, M, additional, Guida, L, additional, Giuffrida, E, additional, Magnano, A, additional, Pluchino, D, additional, Ferracane, C, additional, Magrì, G, additional, Di Mitri, R, additional, Mocciaro, F, additional, Privitera, A C, additional, Camilleri, S, additional, Garufi, S, additional, Renna, S, additional, Casà, A, additional, Scrivo, B, additional, Ventimiglia, M, additional, and Orlando, A, additional

Published
2021
Full Text
View/download PDF

19. P436 SPOSAB ABP 501 - A Sicilian Prospective Observational Study of Patients with Inflammatory Bowel Disease Treated with Adalimumab Biosimilar ABP 501

Author

Macaluso, F, primary, Cappello, M, additional, Busacca, A, additional, Fries, W, additional, Viola, A, additional, Costantino, G, additional, Magnano, A, additional, Vinci, E, additional, Ferracane, C, additional, Privitera, A C, additional, Piccillo, G, additional, Belluardo, N, additional, Giangreco, E, additional, Romano, C, additional, Citrano, M, additional, Graziano, F, additional, Garufi, S, additional, Bertolami, C, additional, Scrivo, B, additional, Renna, S, additional, Casà, A, additional, Rizzuto, G, additional, Ventimiglia, M, additional, and Orlando, A, additional

Published
2021
Full Text
View/download PDF

21. P305 Effectiveness and Safety of Vedolizumab in Biologic-Naïve Patients: Real-World Data from the Sicilian Network for Inflammatory Bowel Diseases (SN-IBD)

Author

Macaluso, F, primary, Fries, W, additional, Renna, S, additional, Viola, A, additional, Muscianisi, M, additional, Cappello, M, additional, Guida, L, additional, Siringo, S, additional, Camilleri, S, additional, Garufi, S, additional, Privitera, A C, additional, Belluardo, N, additional, Giangreco, E, additional, Bertolami, C, additional, Vassallo, R, additional, Rizzuto, G, additional, Orlando, R, additional, Ventimiglia, M, additional, and Orlando, A, additional

Published
2021
Full Text
View/download PDF

22. P288 Vedolizumab May Be An Effective Option For The Management Of Postoperative Recurrence Of Crohn’s Disease

Author

Macaluso, F S, primary, Cappello, M, additional, Crispino, F, additional, Grova, M, additional, Privitera, A C, additional, Piccillo, G, additional, Magnano, A, additional, Ferracane, C, additional, Belluardo, N, additional, Giangreco, E, additional, Fries, W, additional, Viola, A, additional, Di Mitri, R, additional, Mocciaro, F, additional, Camilleri, S, additional, Garufi, S, additional, Renna, S, additional, Casà, A, additional, Maida, M, additional, and Orlando, A, additional

Published
2021
Full Text
View/download PDF

33. The Craniovertebral Junction in Rheumatoid Arthritis: State of the Art

Author

Ferrante A., Ciccia F., Giammalva G. R., Iacopino D. G., Visocchi M., Macaluso F., Maugeri R., Ferrante, A., Ciccia, F., Giammalva, G. R., Iacopino, D. G., Visocchi, M., Macaluso, F., and Maugeri, R.

Subjects
Inflammation, Joint Instability, Skull Base, Instrumentation and fusion procedure, Basilar invagination, Craniovertebral junction, Transoral decompression, Atlantoaxial dislocation, Arthritis, Rheumatoid, Atlanto-Axial Joint, Cervical spine, Cervical Vertebrae, Humans, Atlantoaxial synoviti, Rheumatoid arthriti, Transnasal decompression, Atlantoaxial instability
Abstract

Rheumatoid arthritis (RA) is a chronic inflammatory disorder, characterized by polyarticular inflammation causing progressive joint damage and disability. The mechanisms underlying its pathogenesis involve activation of innate and adaptive immunity, microvascular endothelial cell activation, and inflammatory infiltration of lymphocytes and monocytes into the synovium. Spinal involvement in RA is not typical; when it occurs, the main radiological features are (1) atlantoaxial subluxation (AAS), which is the most typical form of cervical spine involvement; (2) cranial settling—also known as basilar impression, atlantoaxial impaction or superior migration of the odontoid—which is the most severe form of associated spinal instability; and (3) subaxial subluxation. A combination of these alterations may occur. Synovitis is characterized by infiltration of innate and adaptive immune cells; joint destruction is a consequence of activation of synovial fibroblasts, which acquire aggressive, inflammatory, invasive features, associated with increased chondrocyte catabolism and synovial osteoclastogenesis. Neck pain is the most frequent symptom of spinal involvement in RA; it occurs in 40–80% of patients and is mostly localized at the craniocervical junction. Other symptoms—caused by compression of neural structures such as the greater occipital nerve (at C2), the nucleus of the spinal trigeminal tract and the greater auricular nerve—are occipital neuralgia, facial pain and ear pain, respectively. Irritation of the lesser occipital nerve (at C1) can cause pain in the suboccipital region. Sometimes patients may complain of a sensation of their head falling down with flexion, weakness, reduced endurance, loss of ability, gait alterations, paraesthesias or other symptoms due to cord and medullary compression, and upper or lower motor neuron signs, or both. Surgical management of RA remains a challenging field.

Published
2019

35. Real time magnetic resonance guided endomyocardial local delivery

Author

Cori, R., Badimon, J., Mizsei, G., Macaluso, F., Lee, M., Licato, P., Viles-Gonzalez, J.F., Fuster, V., and Sherman, W.

Subjects
Heart diseases -- Care and treatment, Heart diseases -- Research, Magnetic resonance imaging -- Usage, Health
Published
2005

36. Water channel-carrying vesicles in the rat IMCD contain cellubrevin

Author

Franki, N., Macaluso, F., Schubert, W., Gunther, L., and Hays, R.M.

Subjects
Proteins -- Observations, Kidneys -- Physiological aspects, Biological sciences
Abstract

Coated and uncoated vesicles in rat inner medullary collecting ducts and multivesicular bodies contain cellubrevin, a member of vesicle-associated membrane protein family. Exocytic and endocytic pathways of water channel cycling contain cellbrevin. It is also present on apical membrane. One or two steps in arginine vasopressin-induced water channel cycling are mediated by cellubrevin.

Published
1995

37. Procedimento per la sintesi di esosomi contenenti proteine da shock termico e loro uso per il trattamento della atrofia muscolare e della cachessia

Author

Di Felice V., Farina F., Cappello F., Campanella C., Barone R., Marino Gammazza A., Trovato E., D'Amico D., Macaluso F., Coletti D., Adamo S., Multhoff G., Gasco P., and Di Felice V., Farina F., Cappello F., Campanella C., Barone R., Marino Gammazza A., Trovato E., D'Amico D., Macaluso F., Coletti D., Adamo S., Multhoff G., Gasco P.

Subjects
Settore BIO/16 - Anatomia Umana, cachexia, skelethal muscle, exosomes, extracellular vescicles, Hsp60
Published
2018

39. P717 Ustekinumab in Crohn’s disease: Real-world outcomes from the Sicilian Network for inflammatory bowel diseases (SN-IBD):–Preliminary results

Author

Viola, A, primary, Fiocco, G, additional, Alibrandi, A, additional, Macaluso, F S, additional, Cappello, M, additional, Privitera, A C, additional, Magrì, G, additional, Garufi, S, additional, Centritto, A, additional, Ventimiglia, M, additional, Giuffrida, E, additional, Ferracane, C, additional, Costantino, G, additional, Renna, S, additional, Orlando, A, additional, and Fries, W, additional

Published
2020
Full Text
View/download PDF

40. P690 A propensity score weighted comparison of vedolizumab, adalimumab, and golimumab in patients with ulcerative colitis: Real-life data from the Sicilian Network for Inflammatory Bowel Disease (SN-IBD)

Author

Macaluso, F S, primary, Ventimiglia, M, additional, Fries, W, additional, Viola, A, additional, Cappello, M, additional, Scrivo, B, additional, Magnano, A, additional, Pluchino, D, additional, Camilleri, S, additional, Garufi, S, additional, Di Mitri, R, additional, Mocciaro, F, additional, Magrì, G, additional, Ferracane, C, additional, Citrano, M, additional, Graziano, F, additional, Bertolami, C, additional, Renna, S, additional, Orlando, R, additional, Rizzuto, G, additional, Cottone, M, additional, and Orlando, A, additional

Published
2020
Full Text
View/download PDF

41. P425 SPOSIB SB2: a Sicilian prospective observational study of patients with inflammatory bowel disease treated with infliximab biosimilar SB2

Author

Macaluso, F S, primary, Fries, W, additional, Viola, A, additional, Centritto, A, additional, Cappello, M, additional, Giuffrida, E, additional, Privitera, A C, additional, Piccillo, G, additional, Magnano, A, additional, Vinci, E, additional, Vassallo, R, additional, Trovatello, A, additional, Belluardo, N, additional, Giangreco, E, additional, Camilleri, S, additional, Garufi, S, additional, Bertolami, C, additional, Ventimiglia, M, additional, Renna, S, additional, Orlando, R, additional, Rizzuto, G, additional, Grova, M, additional, and Orlando, A, additional

Published
2020
Full Text
View/download PDF

42. P325 A propensity score-weighted comparison of vedolizumab and adalimumab in Crohn’s disease: Real-life data from the Sicilian Network for inflammatory bowel disease (SN-IBD)

Author

Macaluso, F S, primary, Ventimiglia, M, additional, Fries, W, additional, Viola, A, additional, Sitibondo, A, additional, Cappello, M, additional, Scrivo, B, additional, Busacca, A, additional, Privitera, A C, additional, Camilleri, S, additional, Garufi, S, additional, Di Mitri, R, additional, Mocciaro, F, additional, Belluardo, N, additional, Giangreco, E, additional, Bertolami, C, additional, Renna, S, additional, Orlando, R, additional, Rizzuto, G, additional, Cottone, M, additional, and Orlando, A, additional

Published
2020
Full Text
View/download PDF

43. Anti-cancer effects of Pleurotus eryngii var. eryngii: an in vitro and in vivo models focusing on Heat Shock Proteins

Author

Marino Gammazza, A, Barone, R, Gargano, ML, Caruso Bavisotto, C, Macaluso, F, D'Amico, D, TROVATO, Eleonora, Rappa, F, Campanella, C, Di Felice, V, Cappello, F, Venturella, G, Marino Gammazza, A, Barone, R, Gargano, ML, Caruso Bavisotto, C, Macaluso, F, D'Amico, D, Trovato, E, Rappa, F, Campanella, C, Di Felice, V, Cappello, F, and Venturella, G

Subjects
Settore BIO/16 - Anatomia Umana, Settore BIO/03 - Botanica Ambientale E Applicata, Heat Schock Proteins, Pleurotus eryngii var. eryngii, Anti-cancer effects
Abstract

Heat shock proteins (Hsps) are highly expressed in a variety of cancer cells and are essential to their survival contributing to tumor cell propagation, metastasis, and protection against apoptosis]. Cancer is a leading cause of death worldwide. The current anti-cancer drugs available in market are not target specific and pose several side-effects and complications in clinical management of various forms of cancer, which highlights the urgent need for novel effective and less-toxic therapeutic approaches. Medicinal mushrooms have emerged as wonderful source of nutraceuticals, anti-oxidants, anticancer, prebiotic, anti-inflammatory, cardiovascular, anti-microbial, and anti-diabetic. The ongoing research projects are aimed to promote mushrooms as new generation ‘‘biotherapeutics". The aim of this study was to evaluate whether the cold-water extracts of Pleurotus eryngii var. eryngii can affect Hsp90, 70, 60 and 27 levels in an in vitro model of colon cancer (C26 cells). Cell viability was evaluated using MTT assay after treating the cells with different concentrations of extracts (0-1.9 μg/μl) in the culture medium for 24 and 48 hours. Hsp90, 70, 60 and 27 levels were measured using western blotting and immunofluorescence analysis. Moreover, we evaluated the anticancer effect of the P. eryngii var. eryngii extract in an animal model of ectopically-implanted C26 colon carcinoma, widely used as an experimental model of cancer cachexia. We prepared a mixture of lyophilized P. eryngii var. eryngii with the mice standard diet and the animals were daily fed with ~4g of the mix until they died to draw a survival curve. Our results showed that the extract significantly decreased cells viability at 0.48 μg/μl after both 24 and 48 hours of treatments. Western blotting analysis and immunofluorescence showed that Hsp60 protein levels were down-regulate at 24h of treatment but increased after 48h. On the contrary, Hsp90, 70 and 27 protein levels did not changed. In the in vivo model, P. eryngii var. eryngii in the diet significantly extended the median survival compared to untreated mice. These preliminary results are promising for further studies to better understand the potential anticancer effect of P. eryngii var. eryngii.

Published
2017

44. AISF position paper on HCV in immunocompromised patients

Author

Angelucci, E, Astegiano, M, Baratelli, C, Biancone, L, Bironzo, P, Brancaccio, G, Brunetto, M, Bruno, R, Burra, P, Cabras, M, l Caraceni, P, Chialà, C, Clemente, M, Colli, A, Daniele, B, De Gasperi, E, Di Marco, V, Ditto, M, Fagiuoli, S, Ferri, C, Gaeta, G, Grossi, P, Imperatrice, B, Lampertico, P, Macaluso, F, Madonia, S, Marignani, M, Mazzarelli, C, Mella, A, Missale, G, Parisi, S, Pasulo, L, Puoti, M, Rendina, M, Ribaldone, D, Rossi, G, Toniutto, P, Tucci, A, Vajro, P, Viganò, M, Volpes, R, Zignego, A, Giannini, E, Miele, L, Russo, F, Petta, S, Bonora, S, Brignardello, E, Busca, A, Cariti, G, Cavallo, F, Conforti, M, Coscia, M, Craxì, A, Curci, D, Cusinato, S, Di Maio, M, Valle, R, Fusaro, E, Giacardi, A, Giaccone, L, Lagget, M, Libertucci, D, Minutolo, R, Montrucchio, G, Orlando, A, Orsucci, L, Pasquina, C, Pera, A, Peroni, C, Pirisi, M, Racca, P, Riccardini, F, Rizzetto, M, Salizzoni, M, Salomone, M, Saracco, G, Scaglione, L, Torre, G, Tozzi, R, Vitolo, U, Verme, G, Brunetto, MR, Cabras, MG, Clemente, MG, Ditto, MC, Gaeta, GB, Grossi, PA, Macaluso, FS, Zignego, AL, Giannini, EG, Russo, FP, Valle, RD, Peroni, CL, Saracco, GM, Angelucci, E, Astegiano, M, Baratelli, C, Biancone, L, Bironzo, P, Brancaccio, G, Brunetto, M, Bruno, R, Burra, P, Cabras, M, l Caraceni, P, Chialà, C, Clemente, M, Colli, A, Daniele, B, De Gasperi, E, Di Marco, V, Ditto, M, Fagiuoli, S, Ferri, C, Gaeta, G, Grossi, P, Imperatrice, B, Lampertico, P, Macaluso, F, Madonia, S, Marignani, M, Mazzarelli, C, Mella, A, Missale, G, Parisi, S, Pasulo, L, Puoti, M, Rendina, M, Ribaldone, D, Rossi, G, Toniutto, P, Tucci, A, Vajro, P, Viganò, M, Volpes, R, Zignego, A, Giannini, E, Miele, L, Russo, F, Petta, S, Bonora, S, Brignardello, E, Busca, A, Cariti, G, Cavallo, F, Conforti, M, Coscia, M, Craxì, A, Curci, D, Cusinato, S, Di Maio, M, Valle, R, Fusaro, E, Giacardi, A, Giaccone, L, Lagget, M, Libertucci, D, Minutolo, R, Montrucchio, G, Orlando, A, Orsucci, L, Pasquina, C, Pera, A, Peroni, C, Pirisi, M, Racca, P, Riccardini, F, Rizzetto, M, Salizzoni, M, Salomone, M, Saracco, G, Scaglione, L, Torre, G, Tozzi, R, Vitolo, U, Verme, G, Brunetto, MR, Cabras, MG, Clemente, MG, Ditto, MC, Gaeta, GB, Grossi, PA, Macaluso, FS, Zignego, AL, Giannini, EG, Russo, FP, Valle, RD, Peroni, CL, and Saracco, GM

Abstract

This report summarizes the clinical features and the indications for treating HCV infection in immunocompromised and transplanted patients in the Direct Acting Antiviral drugs era.

Published
2019

45. Sicilian Network for Inflammatory Bowel Disease (SN-IBD). A propensity score-matched comparison of infliximab and adalimumab in naïve and non-naïve patients with Crohn’s disease

Author

Orlando, A., Macaluso, F., Fries, W., Privitera, A., Cappello, M., Siringo, S., Inserra, G., Magnano, A., Di Mitri, R., Belluardo, N., Scarpulla, G., Magrì, G., Trovatello, N., Carroccio, A., Genova, S., Bertolami, C., Vassallo, R., Ventimiglia, M., Renna, S., Orlando, R., Rizzuto, G., Cottone, M., and Orlando A., Macaluso F.S., Fries W., Privitera A.C., Cappello M., Siringo S., Inserra G., Magnano A., Di Mitri R., Belluardo N., Scarpulla G., Magrì G., Trovatello N., Carroccio A., Genova S., Bertolami C., Vassallo R., Ventimiglia M., Renna S., Orlando R., Rizzuto G, Cottone M.

Subjects
Sicilian Network, Inflammatory Bowel Disease, SN-IBD, Settore MED/09 - Medicina Interna
Abstract

Background: In the absence of head-to-head trials, there is an unmeet need to better understand the relative effectiveness of different biologics in inflammatory bowel disease (IBD). The Sicilian Network for Inflammatory Bowel Disease (SN-IBD) is a group composed by all Sicilian centres which continuously enter in a web-based software all clinical data of IBD patients treated with biologics. Methods: Data of all incident Crohn’s disease (CD) patients treated with infliximab (IFX) and adalimumab (ADA) from January 2013 to April 2017 were extracted from the cohort of SN-IBD. Patients were divided in biologic-naïve and non-naïve, and the two groups were analysed singularly. We used a one-to-two propensity score matching (1 IFX: 2 ADA) accounting for the main baseline characteristics in naïve patients, and a one-to-one propensity score matching (1 IFX: 1 ADA) in non-naïve. Results: Seven hundred and forty-seven naïve and 188 non-naïve patients were included. After propensity score matching, 453 naïve (IFX: 151; ADA: 302) and 100 non-naïve patients (total treatments: 122; IFX: 61; ADA: 61) were analysed. Among naïve patients, the rates of response/remission at 12 weeks for IFX and ADA were 80.1% and 81.1%,, respectively (adjusted OR 0.97, p = 0.923); over a median follow-up of 11.8 months, the rates of response/remission for IFX and ADA were 70.2% and 66.2%, respectively, without significant differences (adjusted OR 1.14, p = 0.401). Among non-naïve patients, the rates of response/remission at 12 weeks for IFX and ADA were 68.9% and 60.7%, respectively (adjusted OR 1.54, p = 0.320); over a median follow-up of 8.9 months, the rates of response/remission for IFX and ADA were 57.4% and 54.1%, respectively, without significant differences (adjusted OR 1.96, p = 0.297). Cox regression analysis showed no differences in risk of treatment failure between ADA and IFX, neither in naïve (adjusted HR 1.23, p = 0.381) nor in non-naïve patients (adjusted HR 1.23, p = 0.488). At multivariable conditional logistic regression analysis of naïve CD patients, upper GI involvement (OR 0.18, p = 0.038), previous surgery (OR 0.24, p = 0.003), and older age (OR 0.97, p = 0.036) were associated with lower clinical benefit at 12 weeks, while previous surgery was the only independent predictor of treatment failure at the end of follow-up (HR 2.13, p = 0.03). Mixed effect Cox analysis showed that non-naïve patients experiencing more than one previous line of treatment with biologics have a significant higher risk of treatment failure compared with those previously treated with one biologic only (HR 2.57, p = 0.002) Conclusions: In this large, propensity score matched, real-life, multicentre, cohort study of CD patients, there was no significant difference in the effectiveness of ADA and IFX. Both drugs showed a good efficacy.

Published
2018

46. P690 Comparative efficacy of vedolizumab and adalimumab as second-line therapy in ulcerative colitis patients previously treated with infliximab

Author

Favale, A, primary, Onali, S, additional, Caprioli, F, additional, Pugliese, D, additional, Armuzzi, A, additional, Macaluso, F S, additional, Orlando, A, additional, Viola, A, additional, Fries, W, additional, Mocci, G, additional, Chicco, F, additional, Usai, P, additional, Rispo, A, additional, Castiglione, F, additional, Calabrese, E, additional, Biancone, L, additional, Monteleone, G, additional, and Fantini, M C, additional

Published
2019
Full Text
View/download PDF

47. P801 Physicians’ knowledge and application of immunisation strategies in patients with inflammatory bowel disease: a survey by the Italian Group for the study of inflammatory bowel disease (IG-IBD)

Author

Macaluso, F S, primary, Mazzola, G, additional, Ventimiglia, M, additional, Alvisi, P, additional, Renna, S, additional, Adamoli, L, additional, Galli, M, additional, Armuzzi, A, additional, Ardizzone, S, additional, Cascio, A, additional, Cottone, M, additional, and Orlando, A, additional

Published
2019
Full Text
View/download PDF

48. P737 SPOSIB SB2: A Sicilian prospective observational study of patients with inflammatory bowel disease treated with infliximab Biosimilar SB2 (Flixabi®): interim analysis

Author

Macaluso, F S, primary, Cappello, M, additional, Giuffrida, E, additional, Fries, W, additional, Centritto, A, additional, Privitera, A C, additional, Inserra, G, additional, Vassallo, R, additional, Magnano, A, additional, Vinci, E, additional, Garufi, S, additional, Ventimiglia, M, additional, Renna, S, additional, Orlando, R, additional, Rizzuto, G, additional, Cottone, M, additional, and Orlando, A, additional

Published
2019
Full Text
View/download PDF

50. P545 Elderly patients with inflammatory bowel disease (IBD) are less likely to persist on anti-TNF therapy compared with younger patients: data from the Sicilian Network for Inflammatory Bowel Diseases (SN-IBD)

Author

Porcari, S, primary, Fidanza, O, additional, Alibrandi, A, additional, Renna, S, additional, Cappello, M, additional, Siringo, S, additional, Privitera, A, additional, Inserra, G, additional, Mocciaro, F, additional, Magri, G, additional, Carroccio, A, additional, Belluardo, N, additional, Bertolami, C, additional, Garufi, S, additional, Ventimiglia, M, additional, Macaluso, F, additional, Viola, A, additional, Cottone, M, additional, Orlando, A, additional, and Fries, W, additional

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results